
Opinion|Videos|March 10, 2025
Managing Disease Progression After TACE
Author(s)Amit Singal, MD
The panelist discusses how the patient underwent transarterial chemoembolization (TACE) 3 times with an initial partial response. However, at the end of the 6-month treatment period, the patient had disease progression. The panelist advises that the best treatment option for the patient would be systemic therapy.
Advertisement
Video content above is prompted by the following:
- The patient progresses within 1 year of TACE. Please discuss a suitable treatment approach to address disease progression.
- Review case details from the patient’s 6-month follow-up.
- What would your treatment approach look like?
- How would you determine which treatment option would be best for this patient?
Advertisement
Related to this article

During a live event, Robert Orlowski, MD, PhD, and participants discussed selinexor combinations, dosing, and nausea prevention for an older patient with late relapsed multiple myeloma who declines CAR T.

Sac-TMT improved OS vs physician’s choice in pretreated gastroesophageal adenocarcinoma in the phase 3 TroFuse-015 trial; PFS was not improved.

Updated RMC-GI-102 data show 60.7% ORR and 12.8-month median PFS with daraxonrasib plus GnP in first-line metastatic PDAC.

Modern Hodgkin lymphoma treatment is tied to a 25% drop in solid second cancers, but breast and lung cancer risks persist for decades.

ESMO data show the phase 3 INTerpath-001 trial of intismeran autogene plus pembrolizumab improved recurrence-free survival in resected stage IIB to IV melanoma.

In HypoMast-IMNI, 16-fraction radiotherapy was noninferior to 25 fractions for locoregional recurrence after mastectomy in high-risk breast cancer.

Five-year PHERGain results support PET-guided treatment de-escalation in HER2-positive breast cancer, with ctDNA offering insight into recurrence risk
Advertisement
Advertisement
Trending on Targeted Onc
1
Daraxonrasib Plus Chemo Yields Durable Response in First-Line PDAC
2
PET-Guided Strategy May Spare Chemotherapy in HER2-Positive Breast Cancer
3
Treatment Sequencing and Toxicity Are Top Concerns in HER2-Mutant NSCLC
4
Sacituzumab Tirumotecan Improves OS in 3L+ Gastroesophageal Cancer
5

